基于专利视角的京津冀医药制造业协同创新评价  

Collaborative Innovation of Pharmaceutical Manufacturing in Beijing, Tianjin and Hebei Based on Patent Perspective

作　　者：王坤[1] 李春成[2] 马虎兆[2] 

机构地区：[1]河北工业大学经济管理学院,天津300401 [2]天津市科学学研究所,天津300011

出　　处：《科技管理研究》2017年第19期78-84,共7页Science and Technology Management Research

基　　金：国家科技部软科学研究计划项目"国内外现代医药产业创新发展态势和对策研究"(15ZLZLZF00970)

摘　　要：京津冀协同发展已上升到国家战略,其产业协同创新情况到底如何,值得深入研究。选取京津冀地区的医药制造业作为研究对象,采用其1995—2015年相关专利数据建立复合系统协同度模型,对区域内部医药制造业各自和整体的协同度进行测算评价。研究结果表明:(1)区域内专利指标的序参量呈现逐年上升的趋势,说明京津冀地区医药制造业专利方面的创新趋于有序;(2)区域内协同创新子系统中专利价值子系统的重要地位逐渐显现;(3)京津冀医药制造业协同创新水平不断提升,但目前整体协同创新程度仍居于中等水平。The collaborative development of Beijing-Tianjin-Hebei has come to a national strategy, and the process of the collaborative innovation deserve to be studied deeply.This paper selects Beijing, Tianjin and Hebei as the object, describing and analyzing several indicators about pharmaceutical manufacturing of past few years, and then we take data of pharmaceutical manufacturing in Beijing, Tianjin and Hebei range from 1995 to 2015, which related to patent. Based on these data, we set a composite system synergy model to calculate collaborative degree for both the internal pharmaceutical manufacturing respectively and the whole process, which shows that：（1） The trend of order parameter related to patent indicators is increasing, which tells that the creativity in patent is getting better;（2） The importance of patent value subsystem is getting obvious;（3） The collaborative innovation in phamlaceutical manufacturing in Beijing, Tianjin and Hebei is improving quickly, but it still stick on the medium level. So it is still necessary to coordinate the internal subsystem to make sure there will be a high level of collaborative innovation.

关 键 词：协同创新 京津冀 生物医药产业 专利视角 协同度 

分 类 号：F426.72[经济管理—产业经济]